Boston-based Korsana Biosciences emerged from stealth with $175 million in seed and Series A backing to advance KRSA-028, a shuttle-equipped monoclonal antibody targeting amyloid beta, the company announced. Investors include Wellington Management, J.P. Morgan Life Sciences Private Capital and Sanofi Ventures. Korsana expects first-in-human studies in early 2027, with initial safety data midyear and proof-of-concept plaque-reduction readouts by year-end. The financing aims to support development through 2028 and build a broader neurodegeneration pipeline. Korsana’s strategy places it directly in competition with incumbent anti-amyloid approaches and underscores continued investor appetite for high-cost Alzheimer’s antibody programs despite a crowded field.